Cathay Biotech Inc
Cathay Biotech Inc., together with its subsidiaries, engages in the research, development, production, and sale of bio-based materials in China and internationally. The company offers biological long-chain diacids, including sebacic acid and octadecanedioic acid; bio-based polyamides; and bio-based pentamethylene diamine under the TERRYL and ECOPENT brands. It also provides digital solutions for … Read more
Cathay Biotech Inc (688065) - Net Assets
Latest net assets as of September 2025: CN¥21.22 Billion CNY
Based on the latest financial reports, Cathay Biotech Inc (688065) has net assets worth CN¥21.22 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥23.45 Billion) and total liabilities (CN¥2.23 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥21.22 Billion |
| % of Total Assets | 90.5% |
| Annual Growth Rate | 36.97% |
| 5-Year Change | 31.49% |
| 10-Year Change | N/A |
| Growth Volatility | 47.23 |
Cathay Biotech Inc - Net Assets Trend (2016–2024)
This chart illustrates how Cathay Biotech Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Cathay Biotech Inc (2016–2024)
The table below shows the annual net assets of Cathay Biotech Inc from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥15.10 Billion | +2.22% |
| 2023-12-31 | CN¥14.77 Billion | -1.76% |
| 2022-12-31 | CN¥15.04 Billion | +2.39% |
| 2021-12-31 | CN¥14.69 Billion | +27.89% |
| 2020-12-31 | CN¥11.48 Billion | +147.41% |
| 2019-12-31 | CN¥4.64 Billion | +47.05% |
| 2018-12-31 | CN¥3.16 Billion | +43.70% |
| 2017-12-31 | CN¥2.20 Billion | +80.24% |
| 2016-12-31 | CN¥1.22 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Cathay Biotech Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 240549132600.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥2.31 Billion | 20.04% |
| Common Stock | CN¥583.38 Million | 5.07% |
| Other Comprehensive Income | CN¥359.64 Million | 3.13% |
| Other Components | CN¥8.26 Billion | 71.76% |
| Total Equity | CN¥11.51 Billion | 100.00% |
Cathay Biotech Inc Competitors by Market Cap
The table below lists competitors of Cathay Biotech Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
G Mining Ventures Corp
OTCQX:GMINF
|
$1.97 Billion |
|
Hiab B
HE:HIAB
|
$1.97 Billion |
|
Burckhardt Compression Holding AG
LSE:0QNN
|
$1.97 Billion |
|
Kemira Oyj
PINK:KOYJF
|
$1.97 Billion |
|
BUDIMEX A ZY 5
F:FBF
|
$1.97 Billion |
|
Banner Corporation
NASDAQ:BANR
|
$1.97 Billion |
|
Zhejiang Weiming Environment Protection Co Ltd
SHG:603568
|
$1.97 Billion |
|
AVIC Capital Co Ltd
SHG:600705
|
$1.97 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cathay Biotech Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 11,164,180,631 to 11,507,005,495, a change of 342,824,864 (3.1%).
- Net income of 488,961,919 contributed positively to equity growth.
- Dividend payments of 140,834,553 reduced retained earnings.
- Share repurchases of 28,933,667 reduced equity.
- Other comprehensive income increased equity by 133,801,204.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥488.96 Million | +4.25% |
| Dividends Paid | CN¥140.83 Million | -1.22% |
| Share Repurchases | CN¥28.93 Million | -0.25% |
| Other Comprehensive Income | CN¥133.80 Million | +1.16% |
| Other Changes | CN¥-110.17 Million | -0.96% |
| Total Change | CN¥- | 3.07% |
Book Value vs Market Value Analysis
This analysis compares Cathay Biotech Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.86x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 16.84x to 2.86x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | CN¥3.36 | CN¥56.59 | x |
| 2017-12-31 | CN¥6.06 | CN¥56.59 | x |
| 2018-12-31 | CN¥8.70 | CN¥56.59 | x |
| 2019-12-31 | CN¥12.83 | CN¥56.59 | x |
| 2020-12-31 | CN¥27.12 | CN¥56.59 | x |
| 2021-12-31 | CN¥25.66 | CN¥56.59 | x |
| 2022-12-31 | CN¥18.80 | CN¥56.59 | x |
| 2023-12-31 | CN¥19.19 | CN¥56.59 | x |
| 2024-12-31 | CN¥19.77 | CN¥56.59 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cathay Biotech Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.25%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 16.53%
- • Asset Turnover: 0.16x
- • Equity Multiplier: 1.65x
- Recent ROE (4.25%) is below the historical average (8.30%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 11.94% | 15.66% | 0.56x | 1.36x | CN¥23.59 Million |
| 2017 | 15.15% | 24.42% | 0.43x | 1.43x | CN¥113.05 Million |
| 2018 | 14.77% | 26.54% | 0.36x | 1.53x | CN¥150.62 Million |
| 2019 | 10.32% | 24.99% | 0.32x | 1.29x | CN¥14.69 Million |
| 2020 | 4.41% | 30.57% | 0.12x | 1.17x | CN¥-580.80 Million |
| 2021 | 5.58% | 25.16% | 0.15x | 1.52x | CN¥-471.79 Million |
| 2022 | 5.05% | 22.66% | 0.14x | 1.63x | CN¥-541.63 Million |
| 2023 | 3.28% | 17.34% | 0.11x | 1.69x | CN¥-749.89 Million |
| 2024 | 4.25% | 16.53% | 0.16x | 1.65x | CN¥-661.74 Million |
Industry Comparison
This section compares Cathay Biotech Inc's net assets metrics with peer companies in the Chemicals industry.
Industry Context
- Industry: Chemicals
- Average net assets among peers: $2,626,916,213
- Average return on equity (ROE) among peers: 12.41%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cathay Biotech Inc (688065) | CN¥21.22 Billion | 11.94% | 0.11x | $1.97 Billion |
| North Huajin Chemical Industries Co Ltd (000059) | $6.22 Billion | 3.15% | 2.45x | $677.73 Million |
| Jiangsu Wujiang China Eastern Silk Market Co Ltd (000301) | $1.22 Billion | 8.90% | 0.47x | $2.89 Billion |
| Zangge Holding Co Ltd (000408) | $13.85 Billion | 18.63% | 0.09x | $11.87 Billion |
| Sichuan Jinlu Group Co Ltd (000510) | $31.03 Million | 11.65% | 3.42x | $1.15 Billion |
| Jilin Gpro Titanium Industry Co Ltd (000545) | $258.76 Million | 6.78% | 0.30x | $423.89 Million |
| Aoyuan Beauty Valley Technology Co Ltd (000615) | $54.68 Million | 39.27% | 1.16x | $225.85 Million |
| Ningxia Younglight Chemicals Co Ltd (000635) | $184.46 Million | 13.30% | 2.58x | $295.21 Million |
| Maoming Petro-Chemical Shihua Co Ltd (000637) | $691.87 Million | 1.61% | 0.02x | $187.22 Million |
| Shenyang Chemical Industry Co Ltd (000698) | $3.01 Billion | 7.14% | 1.28x | $240.44 Million |
| Hubei Shuanghuan Science and Technology Stock Co Ltd (000707) | $759.12 Million | 13.65% | 0.22x | $412.94 Million |